Finedix BV
2
21M
2
1
- Areas of investment
Summary
Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund. Among the most successful fund investment fields, there is Biotechnology. Among the various public portfolio startups of the fund, we may underline ConjuChem
The common things for fund are deals in the range of 5 - 10 millions dollars.
The usual cause for the fund is to invest in rounds with 4 partakers. The meaningful sponsors for the fund in investment in the same round are QIC BioVentures, Business Development Bank of Canada, Auriga Partners. In the next rounds fund is usually obtained by BMO Nesbitt Burns.
Investments analytics
Analytics
- Total investments
- 2
- Lead investments
- 0
- Exits
- 1
- Investments by industry
- Biotechnology (2)
- Health Care (1)
- Medical Device (1)
- Biopharma (1)
- Clinical Trials (1)
- Investments by region
-
- United States (2)
- Peak activity year
- 1999
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 24
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| ConjuChem | 01 Aug 1999 | Biotechnology | Early Stage Venture | 8M | United States, California, Los Angeles |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.